CAJ | 학술논문

近年来，胃肠间质瘤（GIST）在分子标记物、基因检测、靶向治疗药物药效评估等方面的研究有诸多进展。 DOG1、PKC-θ、ETV1等新的标记物的发现有助于提高GIST的检出率，同时为寻找新的靶向治疗的靶点提供了方向。目前伊马替尼作为靶向治疗一线药物对于改善 GIST患者的预后有重要意义，其耐药机制及新的靶向药物的研制仍需要进一步探索研究。该文对GIST分子病理诊断及靶向治疗的研究进展进行综述。
근년래，위장간질류（GIST）재분자표기물、기인검측、파향치료약물약효평고등방면적연구유제다진전。 DOG1、PKC-θ、ETV1등신적표기물적발현유조우제고GIST적검출솔，동시위심조신적파향치료적파점제공료방향。목전이마체니작위파향치료일선약물대우개선 GIST환자적예후유중요의의，기내약궤제급신적파향약물적연제잉수요진일보탐색연구。해문대GIST분자병리진단급파향치료적연구진전진행종술。
In recent years , there are a lot of progress in these areas of gastrointestinal stromal tumor ( GIST) include molecular markers, gene detection, targeted therapy drugs efficacy assessment .Discovery of DOG1, PKC-θ, ETV1 and other new markers helps to improve the detection rate of GIST , and provide new direction for discovering special therapeutic targets .Currently imatinib as first-line drugs for targeted therapy has great significance for impro-ving the prognosis of patients with GIST , mechanisms of drug resistance and the development of new targeted drugs still need further exploration and research .In this paper , the recent advances in molecular pathological diagnosis and targeted therapy of GIST were reviewed .